Genetic Profiling of Glucocorticoid (NR3C1) and Mineralocorticoid (NR3C2) Receptor Polymorphisms before Starting Therapy with Androgen Receptor Inhibitors: A Study of a Patient Who Developed Toxic Myocarditis after Enzalutamide Treatment

Genetic Profiling of Glucocorticoid (NR3C1) and Mineralocorticoid (NR3C2) Receptor Polymorphisms before Starting Therapy with Androgen Receptor Inhibitors: A Study of a Patient Who Developed Toxic Myocarditis after Enzalutamide Treatment

Enzalutamide is a nonsteroidal inhibitor of the androgen receptor (AR) signaling pathway and is used to treat patients with metastatic castration-resistant prostate cancer. However, the risk of cardiovascular-related hospitalization in patients with no contraindications for the use of enzalutamide i...

Full description

Bibliographic Details
Main Authors: Manuel Morales, Pablo Martín-Vasallo, Julio Ávila
Format: Article
Language:English
Published: MDPI AG 2022-05-01
Series:Biomedicines
Subjects:
enzalutamide
mineralocorticoid receptor
androgen receptor
androgen receptor inhibitors
glucocorticoid receptor
toxic myocarditis
Online Access:https://www.mdpi.com/2227-9059/10/6/1271

Similar Items

Similar Items